person · Reporting owner

Nashat Amir

Disclosed activity across 8 companies

Tapewire entity: 38571
SEC CIK: 0001575843

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Camp4 Therapeutics CorpCAMP · Entity 1161	Director · 10% owner	June 10, 2026	June 12, 2026
Cartesian Therapeutics, Inc.SELB · Entity 6015	Director	June 14, 2019	June 18, 2019
FATE THERAPEUTICS INCFATE · Entity 5968	Director	July 31, 2019	August 02, 2019
Metacrine, Inc.MTCR · Entity 115177	Director · 10% owner	May 18, 2022	September 06, 2022
Scholar Rock Holding CorpSRRK · Entity 3721	Director	May 09, 2024	May 13, 2024
Syros Pharmaceuticals, Inc.SYRS · Entity 85437	Director	June 01, 2022	June 02, 2022
aTYR PHARMA INCLIFE · Entity 7233	Director	May 15, 2018	May 17, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Camp4 Therapeutics Corp

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2036-06-09	Direct	28,000	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.

Cartesian Therapeutics, Inc.

Report date June 14, 2019 · Filed June 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-13	Direct	10,000	Reported balance After 2019-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-14 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in full on the earlier of June 14, 2020 or the day immediately prior to the company's 2020 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the earlier of June 14, 2020 or the day immediately prior to the company's 2020 annual meeting of stockholders.

FATE THERAPEUTICS INC

Report date July 31, 2019 · Filed August 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,129,554	Reported balance After 2019-07-31 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-07-31 · Sale · Disposed 30,045 · Balance 1,129,554 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,099,772	Reported balance After 2019-08-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-08-01 · Sale · Disposed 29,782 · Balance 1,099,772 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	22,019	Reported balance After 2019-07-31 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2019-07-31 · Sale · Disposed 586 · Balance 22,019 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	21,438	Reported balance After 2019-08-01 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2019-08-01 · Sale · Disposed 581 · Balance 21,438 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,743	Reported balance After 2019-07-31 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-07-31 · Sale · Disposed 206 · Balance 7,743 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F6: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,539	Reported balance After 2019-08-01 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2019-08-01 · Sale · Disposed 204 · Balance 7,539 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F6: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	11,333	Reported balance After 2019-07-31 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2019-07-31 · Sale · Disposed 302 · Balance 11,333 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F7: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	11,034	Reported balance After 2019-08-01 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2019-08-01 · Sale · Disposed 299 · Balance 11,034 F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F7: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F5: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F6: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F7: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Metacrine, Inc.

Report date May 18, 2022 · Filed September 06, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17	Direct	16,500	Reported balance After 2022-05-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.

Scholar Rock Holding Corp

Report date May 09, 2024 · Filed May 13, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,650,953	Reported balance After 2024-05-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-05-09 · Other · Disposed 472,394 · Balance 1,650,953 F1: Represents a distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners VI, L.P. ("PVP VI") to its partners. F2: The reportable securities are owned directly by PVP VI. Polaris Venture Management Co. VI, L.L.C. ("PVM VI") is the general partner of PVP VI and PVM VI is managed by its managing members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors (collectively, the "Managing Members"). PVM VI may be deemed to have sole voting, investment and dispositive power with respect to the shares held by PVP VI and each of the Reporting Person and the other Managing Members may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVP VI. Each of the Reporting Person, PVM VI and the other Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person, PVM VI or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, F3: (Continued from footnote 2) except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	98,257	Reported balance After 2024-05-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-05-09 · Other · Acquired 98,257 · Balance 98,257 F4: Represents a change in the form of ownership of PVM VI by virtue of the receipt of shares in the in-kind distribution of common stock of the Issuer for no consideration by PVP VI. F5: The reportable securities are owned directly by PVM VI. PVM VI is the general partner of PVP VI and PVM VI is managed by the Managing Members. The Managing Members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVM VI. Each of the Reporting Person and the other Managing Members disclaim beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2024-05-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-05-09 · Other · Disposed 98,257 · Balance 0 F6: Represents a distribution, and not a purchase or sale, without additional consideration by PVM VI to its members. F5: The reportable securities are owned directly by PVM VI. PVM VI is the general partner of PVP VI and PVM VI is managed by the Managing Members. The Managing Members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVM VI. Each of the Reporting Person and the other Managing Members disclaim beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	96,474	Reported balance After 2024-05-09 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2024-05-09 · Other · Disposed 27,606 · Balance 96,474 F8: Represents a distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners Founders' Fund VI, L.P. ("PVPFF VI") to its partners. F9: The reportable securities are owned directly by PVPFF VI. PVM VI is the general partner of PVPFF VI. PVM VI may be deemed to have sole voting, investment and dispositive power with respect to the shares held by PVPFF VI and each of the Reporting Person and the other Managing Members may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVPFF VI. Each of the Reporting Person, PVM VI and the other Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person, PVM VI or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,469	Reported balance After 2024-05-09 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2024-05-09 · Other · Acquired 322 · Balance 1,469 F10: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVPFF VI. F11: The reportable securities are owned by North Star Profit Sharing Trust for the benefit of the Reporting Person.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	276	Reported balance After 2024-05-09 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2024-05-09 · Other · Acquired 276 · Balance 276 F12: Represents a change in the form of ownership of PVM VI by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVPFF VI. F5: The reportable securities are owned directly by PVM VI. PVM VI is the general partner of PVP VI and PVM VI is managed by the Managing Members. The Managing Members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVM VI. Each of the Reporting Person and the other Managing Members disclaim beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2024-05-09 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 8 · 2024-05-09 · Other · Disposed 276 · Balance 0 F6: Represents a distribution, and not a purchase or sale, without additional consideration by PVM VI to its members. F5: The reportable securities are owned directly by PVM VI. PVM VI is the general partner of PVP VI and PVM VI is managed by the Managing Members. The Managing Members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVM VI. Each of the Reporting Person and the other Managing Members disclaim beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	Direct	38,639	Ending reported balance After 2024-05-09 transaction · row 9 2 source rows · reconciled sequence Row 4 · 2024-05-09 · Other · Acquired 13,096 · Balance 38,602 F7: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVM VI. Row 9 · 2024-05-09 · Other · Acquired 37 · Balance 38,639 F7: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVM VI.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners VI, L.P. ("PVP VI") to its partners.

F2: The reportable securities are owned directly by PVP VI. Polaris Venture Management Co. VI, L.L.C. ("PVM VI") is the general partner of PVP VI and PVM VI is managed by its managing members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors (collectively, the "Managing Members"). PVM VI may be deemed to have sole voting, investment and dispositive power with respect to the shares held by PVP VI and each of the Reporting Person and the other Managing Members may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVP VI. Each of the Reporting Person, PVM VI and the other Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person, PVM VI or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose,

F3: (Continued from footnote 2) except to the extent of their respective pecuniary interests therein.

F4: Represents a change in the form of ownership of PVM VI by virtue of the receipt of shares in the in-kind distribution of common stock of the Issuer for no consideration by PVP VI.

F5: The reportable securities are owned directly by PVM VI. PVM VI is the general partner of PVP VI and PVM VI is managed by the Managing Members. The Managing Members, one of whom is the Reporting Person and a member of the Issuer's Board of Directors, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVM VI. Each of the Reporting Person and the other Managing Members disclaim beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F6: Represents a distribution, and not a purchase or sale, without additional consideration by PVM VI to its members.

F7: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVM VI.

F8: Represents a distribution, and not a purchase or sale, without additional consideration by Polaris Venture Partners Founders' Fund VI, L.P. ("PVPFF VI") to its partners.

F9: The reportable securities are owned directly by PVPFF VI. PVM VI is the general partner of PVPFF VI. PVM VI may be deemed to have sole voting, investment and dispositive power with respect to the shares held by PVPFF VI and each of the Reporting Person and the other Managing Members may be deemed to have shared voting, investment and dispositive power with respect to the shares held by PVPFF VI. Each of the Reporting Person, PVM VI and the other Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the Reporting Person, PVM VI or any of the other Managing Members is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F10: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVPFF VI.

F11: The reportable securities are owned by North Star Profit Sharing Trust for the benefit of the Reporting Person.

F12: Represents a change in the form of ownership of PVM VI by virtue of the receipt of shares as a result of the in-kind distribution of common stock of the Issuer for no consideration by PVPFF VI.

Syros Pharmaceuticals, Inc.

Report date June 01, 2022 · Filed June 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2032-05-31	Direct	17,500	Reported balance After 2022-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-01 · Grant · Acquired 17,500 · Balance 17,500 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

aTYR PHARMA INC

Report date May 15, 2018 · Filed May 17, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2028-05-15	Direct	20,000	Reported balance After 2018-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-05-15 · Grant · Acquired 20,000 · Balance 20,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-08-16 transaction · row 1 1 source row Row 1 · 2024-08-16 · Other · Disposed 145 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Partners VII, L.P.	Reported balance After 2024-08-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-08-16 · Other · Disposed 1,860,498 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The shares are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PMC VII. Each of the Reporting Person, David Barrett ("Barrett"), Brian Chee ("Chee"), and Bryce Youngren ("Youngren" and, together with the Reporting Person, Barrett, and Chee, the "Managing Members") are the managing members of PMC VII. F4: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectBy Polaris Entrepreneurs' Fund VII, L.P.	Reported balance After 2024-08-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-08-16 · Other · Disposed 130,153 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F5: The shares are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 9,910 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F8: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The shares are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PMC VII. Each of the Reporting Person, David Barrett ("Barrett"), Brian Chee ("Chee"), and Bryce Youngren ("Youngren" and, together with the Reporting Person, Barrett, and Chee, the "Managing Members") are the managing members of PMC VII.

F4: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F5: The shares are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

F6: The Company Stock Option ("Option") is fully vested.

F7: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F8: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 01, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	204	$22.53	$4,596.00	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 6 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,539 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
August 01, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	581	$22.53	$13,089.58	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 4 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 21,438 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
August 01, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	29,782	$22.53	$670,970.59	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 2 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,099,772 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 31, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	302	$22.53	$6,805.18	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 7 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,333 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 31, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	206	$22.53	$4,641.98	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 5 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,743 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 31, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	586	$22.53	$13,204.63	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 3 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,019 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 31, 2019 Filed Aug 2, 2019 20:32 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	30,045	$22.53	$677,022.01	Disclosure SEC source: 0000899243-19-020915 · doc4.xml · nonDerivative · entry 1 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,129,554 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 30, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	873	$22.51	$19,648.52	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 12 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 11,635 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 30, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	596	$22.51	$13,414.11	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 9 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,949 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 30, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	1,696	$22.51	$38,171.70	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 6 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,605 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 30, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	87,010	$22.51	$1,958,325.37	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 3 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,159,599 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 29, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	3	$22.50	$67.50	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 11 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,508 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 29, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	3	$22.50	$67.50	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 8 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,545 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 29, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	6	$22.50	$135.00	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 5 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,301 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 29, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	317	$22.50	$7,132.50	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 2 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,246,609 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 26, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	270	$22.50	$6,075.03	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 10 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,511 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 26, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	184	$22.50	$4,140.00	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 7 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,548 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 26, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	523	$22.50	$11,767.50	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 4 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,307 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 26, 2019 Filed Jul 30, 2019 22:25 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	26,852	$22.50	$604,170.00	Disclosure SEC source: 0000899243-19-020605 · doc4.xml · nonDerivative · entry 1 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,246,926 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 24, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	192	$22.51	$4,321.09	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 8 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,781 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 24, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	132	$22.51	$2,970.77	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 6 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,732 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 24, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	374	$22.51	$8,417.13	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 4 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,830 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 24, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	19,168	$22.51	$431,389.26	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 2 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,273,778 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 23, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	601	$22.51	$13,525.51	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 7 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,973 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F7 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 23, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	411	$22.51	$9,249.60	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 5 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,864 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F6 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 23, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	1,167	$22.51	$26,263.34	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 3 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,204 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F5 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 23, 2019 Filed Jul 25, 2019 22:24 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	59,854	$22.51	$1,347,014.27	Disclosure SEC source: 0000899243-19-020426 · doc4.xml · nonDerivative · entry 1 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,292,946 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	472	$22.52	$10,631.38	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 12 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,574 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F8 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	323	$22.52	$7,275.35	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 9 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,275 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F7 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	917	$22.52	$20,654.69	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 6 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,371 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F6 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 22, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	46,992	$22.52	$1,058,457.21	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 3 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,352,800 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F4 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	10	$22.50	$225.00	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 11 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,046 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F8 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	7	$22.50	$157.50	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 8 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,598 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F7 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	20	$22.50	$450.00	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 5 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,288 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F6 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 19, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	1,016	$22.50	$22,860.00	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 2 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,399,792 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F4 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 18, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	208	$22.50	$4,680.92	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 10 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,056 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F8 · ownership.nature: The reportable securities are owned directly by PVPSFF V. PVM V is the general partner of PVPSFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPSFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 18, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	142	$22.50	$3,195.61	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 7 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,605 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F7 · ownership.nature: The reportable securities are owned directly by PVPFF V. PVM V is the general partner of PVPFF V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPFF V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 18, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	403	$22.50	$9,069.19	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 4 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,308 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F6 · ownership.nature: The reportable securities are owned directly by PVPE V. PVM V is the general partner of PVPE V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Flint and McGuire are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVPE V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 18, 2019 Filed Jul 22, 2019 21:52 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	SaleCommon Stock	20,656	$22.50	$464,848.82	Disclosure SEC source: 0000899243-19-020033 · doc4.xml · nonDerivative · entry 1 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,400,808 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Polaris Venture Partners V, L.P. ("PVP V"), Polaris Venture Partners Entrepreneurs' Fund V, L.P. ("PVPE V"), Polaris Venture Partners Founders' Fund V, L.P. ("PVPFF V") and Polaris Venture Partners Special Founders' Fund V, L.P. ("PVPSFF V", together with PVP V, PVPE V, PVPFF V, the "Polaris Funds") on June 17, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the United States Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: In prior Form 4 filings, the shares reported in Column 5 were reported as an aggregate number of shares owned by all of the Polaris Funds. The format of the disclosure contained herein has been revised to show the number of securities beneficially owned by each of the Polaris Funds, on a fund by fund basis. F4 · ownership.nature: The reportable securities are owned directly by PVP V. Polaris Venture Management Co. V, L.L.C. ("PVM V") is the general partner of PVP V. The Reporting Person, a member of the Issuer's Board of Directors, is a member of PVM V. Each of Jonathan A. Flint ("Flint") and Terrance G. McGuire ("McGuire") are the managing members of PVM V. Each of Flint, McGuire and the Reporting Person, in their respective capacities with respect to PVM V, may be deemed to have shared voting and dispositive power over the shares held by PVP V. Each of PVM V, Flint, McGuire and the Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries B Preferred Stock · Derivative	24,111	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 14 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 24,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries A Preferred Stock · Derivative	86,487	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 13 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 86,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries Seed Preferred Stock · Derivative	33,108	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 12 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 33,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries B Preferred Stock · Derivative	344,662	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 11 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Partners VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 344,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.exercise_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F5 · derivative.expiration_date: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, David Barrett ("Barrett"), Brian Chee ("Chee"), Jonathan A. Flint ("Flint"), Terrance G. McGuire ("McGuire") and Bryce Youngren ("Youngren" and, together with the reporting person, Barrett, Chee, Flint, and McGuire, the "Managing Members") are the managing members of PMC VII. F3 · ownership.nature: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries A Preferred Stock · Derivative	1,236,302	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 10 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Partners VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,236,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, David Barrett ("Barrett"), Brian Chee ("Chee"), Jonathan A. Flint ("Flint"), Terrance G. McGuire ("McGuire") and Bryce Youngren ("Youngren" and, together with the reporting person, Barrett, Chee, Flint, and McGuire, the "Managing Members") are the managing members of PMC VII. F3 · ownership.nature: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionSeries Seed Preferred Stock · Derivative	473,276	$0.00	$0.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · derivative · entry 9 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Partners VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 473,276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, David Barrett ("Barrett"), Brian Chee ("Chee"), Jonathan A. Flint ("Flint"), Terrance G. McGuire ("McGuire") and Bryce Youngren ("Youngren" and, together with the reporting person, Barrett, Chee, Flint, and McGuire, the "Managing Members") are the managing members of PMC VII. F3 · ownership.nature: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	8,173	$15.00	$122,595.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · nonDerivative · entry 8 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 151,879 F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	PurchaseCommon Stock	116,827	$15.00	$1,752,405.00	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · nonDerivative · entry 7 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Partners VII, L.P. Disclosed balance after: 2,171,067 F2 · ownership.nature: The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, David Barrett ("Barrett"), Brian Chee ("Chee"), Jonathan A. Flint ("Flint"), Terrance G. McGuire ("McGuire") and Bryce Youngren ("Youngren" and, together with the reporting person, Barrett, Chee, Flint, and McGuire, the "Managing Members") are the managing members of PMC VII. F3 · ownership.nature: Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	24,111	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · nonDerivative · entry 6 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 143,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	86,487	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · nonDerivative · entry 5 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 119,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document
July 01, 2019 Filed Jul 1, 2019 19:19 UTC	Morphic Holding, Inc. MORF · Entity 88114	ConversionCommon Stock	33,108	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-19-008259 · edgar.xml · nonDerivative · entry 4 Nashat Amir · CIK 0001575843 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VII, L.P. Disclosed balance after: 33,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series Seed Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F6 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. The reporting person, a member of the issuer's Board of Directors, is a member of PMC VII. Each of the reporting person, Barrett, Chee, Flint, McGuire and Youngren are the managing members of PMC VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.